121 related articles for article (PubMed ID: 36800852)
1. Universal Repeat Screening for Human Immunodeficiency Virus in the Third Trimester of Pregnancy: A Cost-Effectiveness Analysis.
Hawkinson LF; Chaiken SR; Doshi U; Wallace J; Caughey AB
Obstet Gynecol; 2023 Mar; 141(3):535-543. PubMed ID: 36800852
[TBL] [Abstract][Full Text] [Related]
2. Repeat Screening for Syphilis in the Third Trimester of Pregnancy: A Cost-Effectiveness Analysis.
Hersh AR; Megli CJ; Caughey AB
Obstet Gynecol; 2018 Sep; 132(3):699-707. PubMed ID: 30095767
[TBL] [Abstract][Full Text] [Related]
3. Universal Rapid Human Immunodeficiency Virus Screening at Delivery: A Cost-Effectiveness Analysis.
Scott RK; Crochet S; Huang CC
Infect Dis Obstet Gynecol; 2018; 2018():6024698. PubMed ID: 29731602
[TBL] [Abstract][Full Text] [Related]
4. Herpes Simplex Virus Serotyping in Pregnant Women With a History of Genital Herpes and an Outbreak in the Third Trimester of Pregnancy: A Cost-Effectiveness Analysis.
Chatroux IC; Hersh AR; Caughey AB
Obstet Gynecol; 2021 Jan; 137(1):63-71. PubMed ID: 33278294
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of universal compared with voluntary screening for human immunodeficiency virus among pregnant women in Chicago.
Immergluck LC; Cull WL; Schwartz A; Elstein AS
Pediatrics; 2000 Apr; 105(4):E54. PubMed ID: 10742375
[TBL] [Abstract][Full Text] [Related]
6. Universal Hepatitis B Antibody Screening and Vaccination in Pregnancy: A Cost-Effectiveness Analysis.
Prabhu M; Susich MK; Packer CH; Hersch AR; Riley LE; Caughey AB
Obstet Gynecol; 2022 Mar; 139(3):357-367. PubMed ID: 35115449
[TBL] [Abstract][Full Text] [Related]
7. Human immunodeficiency virus retesting during pregnancy: costs and effectiveness in preventing perinatal transmission.
Sansom SL; Jamieson DJ; Farnham PG; Bulterys M; Fowler MG
Obstet Gynecol; 2003 Oct; 102(4):782-90. PubMed ID: 14551009
[TBL] [Abstract][Full Text] [Related]
8. Universal first-trimester cytomegalovirus screening and valaciclovir prophylaxis in pregnant persons: a cost-effectiveness analysis.
Fisher SA; Miller ES; Yee LM; Grobman WA; Premkumar A
Am J Obstet Gynecol MFM; 2022 Sep; 4(5):100676. PubMed ID: 35714861
[TBL] [Abstract][Full Text] [Related]
9. Cost Effectiveness of Latest Recommendations for Group B Streptococci Screening in the United States.
Williams M; Zantow E; Turrentine M
Obstet Gynecol; 2020 Apr; 135(4):789-798. PubMed ID: 32168204
[TBL] [Abstract][Full Text] [Related]
10. A cost-effectiveness analysis of universal hepatitis C screening in all United States pregnancies.
Susich M; Hersh AR; Greiner K; Chaiken SR; Caughey AB
J Matern Fetal Neonatal Med; 2022 Dec; 35(25):7381-7388. PubMed ID: 34392786
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of cervical length screening and progesterone treatment to prevent spontaneous preterm delivery in Sweden.
Wikström T; Kuusela P; Jacobsson B; Hagberg H; Lindgren P; Svensson M; Wennerholm UB; Valentin L
Ultrasound Obstet Gynecol; 2022 Jun; 59(6):778-792. PubMed ID: 35195310
[TBL] [Abstract][Full Text] [Related]
12. Positivity thresholds of HbA1c assay as a screening test for diabetes mellitus in the first trimester in high-risk populations.
Walker AR; Caughey AB
J Matern Fetal Neonatal Med; 2022 Jan; 35(2):230-234. PubMed ID: 32146861
[TBL] [Abstract][Full Text] [Related]
13. Point-of-care HIV viral load in pregnant women without prenatal care: a cost-effectiveness analysis.
Avram CM; Greiner KS; Tilden E; Caughey AB
Am J Obstet Gynecol; 2019 Sep; 221(3):265.e1-265.e9. PubMed ID: 31229430
[TBL] [Abstract][Full Text] [Related]
14. Third-trimester repeat HIV testing: it is time we make it universal.
Cassimatis IR; Ayala LD; Miller ES; Garcia PM; Jao J; Yee LM
Am J Obstet Gynecol; 2021 Nov; 225(5):494-499. PubMed ID: 33932342
[TBL] [Abstract][Full Text] [Related]
15. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs.
Paltiel AD; Walensky RP; Schackman BR; Seage GR; Mercincavage LM; Weinstein MC; Freedberg KA
Ann Intern Med; 2006 Dec; 145(11):797-806. PubMed ID: 17146064
[TBL] [Abstract][Full Text] [Related]
16. How much should we pay for a new HIV diagnosis? A mathematical model of HIV screening in US clinical settings.
Farnham PG; Sansom SL; Hutchinson AB
Med Decis Making; 2012; 32(3):459-69. PubMed ID: 22247422
[TBL] [Abstract][Full Text] [Related]
17. Cost Effectiveness of Neonatal Resuscitation at 22 Weeks of Gestation.
Yieh L; Dukhovny D; Zhou CG; Gievers L; Caughey AB
Obstet Gynecol; 2019 Jun; 133(6):1199-1207. PubMed ID: 31135735
[TBL] [Abstract][Full Text] [Related]
18. First trimester fasting plasma glucose screen in advanced maternal age women: a cost-effectiveness analysis.
Waites BT; Walker AR; Skeith AA; Caughey AB
J Matern Fetal Neonatal Med; 2022 Nov; 35(21):4123-4129. PubMed ID: 33179564
[TBL] [Abstract][Full Text] [Related]
19. [Cost-effectiveness analysis of universal screening for thyroid disease in pregnant women in Spain].
Donnay Candil S; Balsa Barro JA; Álvarez Hernández J; Crespo Palomo C; Pérez-Alcántara F; Polanco Sánchez C
Endocrinol Nutr; 2015; 62(7):322-30. PubMed ID: 25977144
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of ultrasound before non-invasive prenatal screening for fetal aneuploidy.
Battarbee AN; Vora NL; Hardisty EE; Stamilio DM
Ultrasound Obstet Gynecol; 2023 Mar; 61(3):325-332. PubMed ID: 36273429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
